InvestorsHub Logo
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Re: None

Friday, 05/16/2008 5:39:03 PM

Friday, May 16, 2008 5:39:03 PM

Post# of 145
StatSure Diagnostic Systems, Inc. Announces First Quarter Revenues and Management Changes

Last update: 3:14 p.m. EDT May 16, 2008

NEW YORK, May 16, 2008 (BUSINESS WIRE) -- StatSure Diagnostic Systems, Inc. (OTCBB: "SSUR") today announced its financial results for the three months ended March 31, 2008. The increase in revenue for the three months in 2008 consists of greater sales of our saliva collectors and an increase in license fees from the Company's various license agreements with ChemBio and Inverness.


Three Months Ended March 31, 

2008 2007
-------- --------
Product Sales $224,370 $142,862
Royalty and Other Income 35,800 10,986
Selling, general and administrative expenses 244,579 495,604

Additionally, the Company announced that effective July 1, 2008, Mr. Steve M. Peltzman, Chairman of the Board and Chief Executive Officer, and Mr. D. Bruce Pattison, President, Chief Operating Officer and Director, have resigned. Messrs Peltzman and Pattison, have indicated that they will enter into Consulting Agreements with StatSure. In addition, Mr. Richard Woodrich has resigned as Director. Concurrently, the Board elected Mr. Moishe Bodner, currently Vice President of the Company, as Chief Executive Officer and Director, and Mr. Leo Ehrlich, the current Chief Financial Officer and Director, was elected as the President, Chief Operating Officer effective July 1, 2008.

The incoming Chief Executive Officer noted that the Company accepted the resignations of Mr. Peltzman and Mr. Pattison with regret, and thanked them for their services. As Mr. Bodner pointed out, "Their commercial leadership and expertise with respect to strategic partnering and regulatory affairs raised StatSure to a new level in consummating the transactions with Inverness and ChemBio, as well as other transactions which will allow us to increase the revenues and margins from our existing products and technology. While they have reduced their time commitments to the Company, StatSure will be able to avail itself of their knowledge and expertise as consultants to the Company."

The Company also announced that it had been granted a patent on one of its key technologies in Brazil.

About StatSure
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.

Please visit our website at http://www.StatSure.com.

StatSure Diagnostic Systems, Inc.
http://www.StatSure.com
SOURCE: StatSure Diagnostic Systems, Inc.

StatSure Diagnostic Systems, Inc.
Mo Bodner, 347-394-3641
mobodner@statsure.com


Copyright Business Wire 2008

The SEC Must Go!
And jail shorters.